Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tyndallized lactic acid bacteria
- Development stage
- Unknown
- Lead developer
- Noventure
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Tyndallized lactic acid bacteria are heat-inactivated microorganisms that function as postbiotics to treat gastrointestinal disorders. The tyndallization process involves a specific heat-treatment protocol that renders the bacteria non-viable while preserving the structural integrity of the bacterial cell wall and its metabolic byproducts. These components, including peptidoglycans and lipoteichoic acids, interact with the host's intestinal environment to support the mucosal barrier and modulate the composition of the gut microbiota. In clinical practice, these postbiotics are primarily indicated for the management of chronic diarrhea and intestinal dysbiosis. They are frequently formulated in combination with mucosal protectors, such as gelatin tannate, to provide a synergistic effect in restoring gut homeostasis and physiological barrier function. This approach is particularly advantageous as it avoids the potential risks associated with live bacterial translocation while retaining the beneficial biological activities of the microorganisms.
- Other names
- heat-killed lactic acid bacteriainactivated lactic acid bacteriapostbiotics
02
Targets
TLR2 (Toll-like Receptor 2)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on tyndallized lactic acid bacteria.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tyndallized lactic acid bacteria.